AGM/EGM17 Aug 2026, 12:21 pm
Indegene Appoints Jill Mary De Simone as Independent Director
AI Summary
Indegene Ltd announced the appointment of Ms. Jill Mary De Simone as an Independent Director, approved by shareholders at the 28th Annual General Meeting held on August 13, 2026. Ms. De Simone's term is for three years, effective January 22, 2026, to January 21, 2029. She brings extensive experience from leadership roles in biopharmaceutical companies like Merck, Teva, and Bristol Myers Squibb, with expertise in oncology, HIV, and general medicine. Currently, she advises life sciences companies and serves on boards, focusing on commercialization and AI in healthcare. She is not related to any existing director and is not debarred from holding a directorship.
Key Highlights
- Ms. Jill Mary De Simone appointed as Independent Director.
- Appointment approved at the 28th Annual General Meeting.
- Term of appointment is 3 years, effective Jan 22, 2026.
- Director brings extensive biopharmaceutical and governance experience.
- No disclosed relationship with existing directors.
Price Impact
More from INDGN